(Q35920086)

11 August 2017

1 reference

title

Lack of evidence for use of glatiramer acetate in multiple sclerosis (English)

1 reference

11 August 2017

0 references

Luca M Munari

1

1 reference

PubMed ID

15488453

11 August 2017

Graziella Filippini

series ordinal

2

1 reference

11 August 2017

1 November 2004

1 reference

11 August 2017

1 reference

11 August 2017

3

1 reference

11 August 2017

641

1 reference

11 August 2017

11

1 reference

Interferons in relapsing remitting multiple sclerosis: a systematic review

11 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900899-3

7 January 2021

A pilot trial of Cop 1 in exacerbating-remitting multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900899-3

7 January 2021

A placebo-controlled, double-blind, randomized, two-center, pilot trial of Cop 1 in chronic progressive multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900899-3

7 January 2021

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900899-3

7 January 2021

European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900899-3

7 January 2021

Surrogate endpoints in clinical trials: definition and operational criteria

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900899-3

7 January 2021

10.1016/S1474-4422(04)00899-3

Identifiers

DOI

1 reference

11 August 2017

1 reference

PubMed ID

15488453